Amylin Analogs and Cagrilintide Receptor Research Overview

Amylin receptor research is a useful case study in how receptor identity itself can be a moving target. There is no single gene called "the amylin receptor": the receptors are assembled from a calcitonin receptor and an accessory protein, and the combination determines pharmacology. This article covers how those receptors are built, what the published pharmacology of cagrilintide shows, how structural biology has clarified the picture, and how these systems differ from the multi-receptor agonist class that includes retatrutide.

Amylin and its parent gene

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-residue peptide co-secreted with insulin from pancreatic beta cells. Structurally it belongs to the calcitonin family, sharing an N-terminal disulfide-bonded ring and a C-terminal amide with calcitonin, CGRP and adrenomedullin. A 2015 Pharmacological Reviews article covers its pharmacology and physiology in depth [1].

Human amylin has a well-known experimental problem: a segment in the middle of the sequence drives amyloid fibril formation, and the peptide aggregates readily in aqueous solution. Rat amylin, which differs at three proline positions, does not. This is why so much amylin work uses rat amylin or engineered analogs, and why any concentration-response curve generated with human amylin must be interpreted with aggregation state in mind.

How RAMPs build a receptor

The calcitonin receptor (CTR) is a class B G protein-coupled receptor. On its own it responds to calcitonin. Christopoulos and colleagues reported in 1999 that co-expressing CTR with receptor activity-modifying proteins generates receptors with amylin pharmacology [2]:

Complex	Composition	Character
CTR alone	Calcitonin receptor	Calcitonin-preferring
AMY1	CTR + RAMP1	Amylin-responsive; also responsive to CGRP in many systems
AMY2	CTR + RAMP2	Amylin-responsive; least well characterized
AMY3	CTR + RAMP3	Amylin-responsive

RAMPs are single-transmembrane accessory proteins that chaperone the receptor to the surface and, critically, alter its ligand-binding pocket. The same principle operates for the calcitonin receptor-like receptor (CLR), where RAMP1 yields a CGRP receptor and RAMP2/3 yield adrenomedullin receptors.

The practical consequence for experimental design is large: a cell line's apparent amylin pharmacology depends on its endogenous RAMP complement, which is rarely reported and often not measured. Transfected systems with defined CTR:RAMP ratios are the standard way to control this, but overexpression ratios themselves influence the result.

Structural clarification

Cao and colleagues published a cryo-electron microscopy analysis in Science in 2022 addressing the structural basis for amylin receptor phenotype, showing how RAMP association reshapes the receptor's peptide-binding interface [3]. Structures of this kind explain why a small accessory protein can convert selectivity so thoroughly, and give medicinal chemists specific contacts to target when designing selective analogs.

Cagrilintide: design and receptor profile

Kruse and colleagues described the development of cagrilintide as a long-acting amylin analog in Journal of Medicinal Chemistry in 2021 [4]. The design problem they set out has three parts, all familiar to peptide chemists:

1. Suppress aggregation. Substitutions in the amyloidogenic region reduce fibril formation.
2. Extend circulating half-life. Lipidation provides albumin binding, the same strategy used across several long-acting peptide classes.
3. Retain receptor activity. Modifications must not abolish engagement of the CTR/RAMP complexes.

Fletcher and colleagues then characterized the compound (as AM833) pharmacologically, comparing it against six selective and nonselective agonists across calcitonin-family GPCRs [5]. That kind of side-by-side profiling is the right reference point for anyone designing a selectivity experiment, because it reports activity at CTR and at the AMY complexes under matched conditions rather than in isolation.

Key methodological points from this literature:

• Signalling readout matters. Class B receptors couple primarily to Gs and cAMP, but β-arrestin recruitment and receptor internalization can dissociate from cAMP, producing biased profiles. Reporting only cAMP may miss this.
• Receptor reserve distorts potency. In high-expression systems, EC50 values shift left. Comparisons across labs require matched expression or normalization to a common reference agonist.
• Albumin in the assay buffer alters free concentration of lipidated peptides substantially. Assays run with and without albumin can differ by orders of magnitude in apparent potency.

A different class: multi-receptor class B agonists

Retatrutide belongs to a separate pharmacological category. Coskun and colleagues described it in Cell Metabolism in 2022 as a peptide engineered to act at three class B receptors at once: the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) [6]. Li and colleagues subsequently reported structural insights into how a single sequence achieves agonism at all three, in Cell Discovery in 2024 [7].

The contrast with amylin analogs is instructive:

	Amylin analogs	Retatrutide
Receptor family	CTR + RAMP heteromers	Class B secretin-family receptors
Number of targets	AMY1/2/3 (and CTR)	GLP-1R, GIPR, GCGR
Selectivity challenge	Distinguishing CTR from AMY complexes	Balancing potency ratios across three receptors
Structural determinant	RAMP-shaped binding interface [3]	Sequence accommodating three distinct pockets [7]

Both compounds have been evaluated in clinical trials; in a laboratory setting the relevant literature is the receptor pharmacology and structural work cited here.

Practical assay design

Choose and report your cell system. State the receptor and RAMP constructs, their ratio, and whether endogenous RAMPs are present. HEK293 cells, for example, express RAMPs endogenously at levels that vary between sublines.

Run a full agonist panel. Comparing a test analog against amylin, calcitonin and CGRP across CTR, AMY1 and AMY3 gives a selectivity fingerprint rather than a single number, in the spirit of the published comparison study [5].

Control peptide handling. For aggregation-prone sequences:

• Prepare fresh solutions and filter or centrifuge before use.
• Consider thioflavin T fluorescence as a quick aggregation check.
• Keep lyophilized material cold and dry; our article on lyophilized peptide storage and stability covers the relevant variables.
• Include low-binding plasticware for lipidated peptides, which adsorb readily.

Verify identity before pharmacology. Lipidated and amidated peptides have distinctive exact masses, and a C-terminal amide differs from the free acid by 1 Da. Reading the analytical package carefully is the first step; our guide on how to read a certificate of analysis explains what each section reports, and per-lot data for our catalog is on the lab reports page.

Open questions

• AMY2 remains poorly characterized relative to AMY1 and AMY3, partly because of difficulty in obtaining clean expression systems.
• RAMP stoichiometry in native tissue is largely unmeasured, so the receptor population being studied in a primary cell is often unknown.
• Biased signalling at AMY receptors has been reported but not systematically mapped across analogs.
• Cross-family interactions between calcitonin-family and secretin-family receptor signalling in the same cell are an open area.

Key takeaways

• Amylin receptors are CTR/RAMP heteromers: RAMP1, RAMP2 and RAMP3 give AMY1, AMY2 and AMY3 [2].
• Human amylin's aggregation propensity is a central experimental constraint and a driver of analog design [1].
• Cagrilintide (AM833) was designed as a long-acting amylin analog and has been profiled against other calcitonin-family agonists [4, 5].
• Cryo-EM work has shown how RAMP association reshapes the receptor's binding interface [3].
• Retatrutide is a distinct class: a single peptide reported to engage GLP-1R, GIPR and GCGR, with structural work published in 2024 [6, 7].

This article summarizes published research for informational purposes. All Ascent Sciences products are for laboratory research use only and are not for human or animal consumption.

References

1. Hay DL, Chen S, Lutz TA, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews. 2015;67(3):564-600. PubMed
2. Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Molecular Pharmacology. 1999;56(1):235-242. PubMed
3. Cao J, Belousoff MJ, Liang YL, et al. A structural basis for amylin receptor phenotype. Science. 2022;375(6587):eabm9609. PubMed
4. Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry. 2021;64(15):11183-11194. PubMed
5. Fletcher MM, Keov P, Truong TT, et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists. Journal of Pharmacology and Experimental Therapeutics. 2021;377(3):417-440. PubMed
6. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. PubMed
7. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10(1):77. PubMed